Oxford Biomedica PLC Total Voting Rights (2145N)
28 Settembre 2021 - 11:01AM
UK Regulatory
TIDMOXB
RNS Number : 2145N
Oxford Biomedica PLC
28 September 2021
Oxford Biomedica
Admission of shares and Total Voting Rights
Oxford, UK - 28 September 2021: Oxford Biomedica plc ("Oxford
Biomedica" or "the Company") (LSE: OXB), announces that further to
the announcement made on 22 September 2021 regarding the
subscription shares to Serum Life Sciences, the Company confirms
that following admission to trading of the 3,382,950 Shares on 27
September, that its issued share capital now consists of 86,075,856
ordinary shares of 50p each. There are no Ordinary Shares held in
treasury.
Accordingly, the total number of voting rights in Oxford
Biomedica plc at the date of this notice is 86,075,856.
The above figure 86,075,856 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Oxford Biomedica plc under the FCA's Disclosure
Guidance and Transparency Rules.
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R)), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb, Sio
Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics and
Boehringer Ingelheim, through which it has long-term economic
interests in other potential gene and cell therapy products.
Additionally, the Group has signed a three-year master supply and
development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate,
AZD1222. Oxford Biomedica is based across several locations in
Oxfordshire, UK and employs more than 740 people. Further
information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREAPNPASNFEEA
(END) Dow Jones Newswires
September 28, 2021 05:01 ET (09:01 GMT)
Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Apr 2023 a Apr 2024